Amyloid-β Monoclonal Antibodies Require <25 Centiloids Plaque Reduction for Cognitive Benefit in Early AD

Alzheimer's disease (AD) is a leading cause of death, characterized by the deposition of extracellular neuritic amyloid-β (Aβ) plaques that disrupt synaptic transmission and cause neuronal death. While Aβ aggregation is a hallmark, not all Aβ-targeting strategies have yielded clinical benefits, highlighting a critical gap in understanding effective therapeutic mechanisms. Current standard-of-care often addresses symptoms rather than disease progression, making disease-modifying therapies a high priority. This review explores how different Aβ species engagement by monoclonal antibodies impacts clinical outcomes.

This narrative review synthesized evidence from clinical trials evaluating monoclonal antibodies (mAbs) designed to target various forms of amyloid-β (Aβ) protein in Alzheimer's disease (AD). The authors examined the mechanisms by which these antibodies aim to reduce amyloid pathology and analyzed their reported clinical outcomes. A key focus was the correlation between the extent of amyloid plaque reduction, measured by amyloid positron emission tomography (PET) scans, and the slowing of cognitive decline, alongside a discussion of amyloid-related imaging abnormalities (ARIA).

The review highlighted that not all Aβ-targeting antibodies, despite engaging different Aβ species (monomers, soluble oligomers, protofibrils, insoluble fibrils/plagues), have demonstrated clinical benefit.

Crucially, achieving amyloid plaque reduction to less than 25 Centiloids, consistent with a visually negative amyloid PET scan, was identified as a strong predictor for slowing cognitive decline in early symptomatic Alzheimer's disease. This suggests that targeting insoluble amyloid plaques is paramount for therapeutic efficacy. The review also detailed the phenomenon of amyloid-related imaging abnormalities (ARIA), including ARIA-E (edema/effusion) and ARIA-H (hemosiderin deposition), which are significant safety considerations associated with Aβ monoclonal antibody therapy. The findings underscore the importance of specific amyloid species engagement for achieving meaningful clinical outcomes.